Physician profile
Luke Webster
NPI 1235660887
$1,474.58
in general payments reported to CMS, 2019-2025
12 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $237 · 2023: $577 · 2024: $16.68 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089 · Education: $26.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.85 |
| Education | $26.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $479.49 | 2021-2023 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $157.51 | 2025 | |
| Novartis Pharmaceuticals Corporation | $140.10 | 2025 | |
| Glaxosmithkline, LLC. | $121.26 | 2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $120.18 | 2023 | |
| Genzyme Corporation | $91.98 | 2023 | |
| Calliditas Therapeutics US INC. | $77.99 | 2023-2025 | Tarpeyo |
| Nxstage Medical, INC. | $75.17 | 2023 | Nxstage System One |
| Mallinckrodt Hospital Products INC. | $69.97 | 2025 | Acthar |
| Ardelyx, INC. | $67.34 | 2025 | Xphozah 30 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.93 | 2024-2025 | Jardiance, Cyltezo |
| Travere Therapeutics, INC. | $26.66 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.